礼来：Retatrutide III期试验达主要终点
2026-07-23 10:49:36
礼来(LLY.N)表示，Retatrutide（瑞他鲁肽）在III期试验中实现了显著的减重效果，并均达到了主要终点。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
礼来计划在2027年第一季度提交Retatrutide申请Next article：
蒙特利尔银行：上调Alphabet目标价至465美元
